IMO, the lack of interest has to do with where they are at with their pipeline. For the most part, they are at the preclinical(theory) stage. When they start to test on humans, and can provide substantial proof of concept, then there could be more interest.
Too bad they aren't trying to test cannabinoids on neurological diseases. That would create a lot of interest in the stock, no matter where they are at in the process (esp this year).
News 
Market Data 
Discover 
